全球肺癌治療市場規模、佔有率、趨勢和成長分析報告（2026-2034）

全球肺癌治療市場預計將從2025年的306.8億美元成長至2034年的896.3億美元，2026年至2034年的複合年成長率（CAGR）為12.65%。該市場正經歷強勁成長，主要受全球肺癌發病率上升和對先進治療方案需求不斷成長的推動。早期診斷意識的提高和醫療服務可近性的改善也促進了市場擴張。製藥公司正大力投資標靶治療、免疫療法和個人化醫療方法，以提高患者的存活率。分子診斷和精準腫瘤學的進步也為創新治療方法的開發做出了重要貢獻。

菸草消費量上升、空氣污染加劇、人口老化是肺癌治療需求的主要促進因素。由於標靶治療和免疫查核點抑制劑相比傳統化療具有更高的療效和更少的副作用，醫療機構正擴大採用這些療法。腫瘤學領域研發活動的活性化以及新治療方法臨床試驗的增加進一步推動了市場成長。此外，政府的支持措施和癌症宣傳活動也對全球治療方法的普及產生了積極影響。

由於生物技術和癌症研究的不斷進步，市場未來前景仍然十分光明。基於基因譜分析的個人化治療方案的開發有望顯著改善治療效果。新興經濟體預計將受益於醫療基礎設施的改善和癌症篩檢計畫的擴大，實現顯著成長。隨著全球肺癌負擔的持續加重，預計整個醫療保健領域的肺癌市場將持續長期擴張。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭動態以及主要參與者所採取的策略。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：這是對主要地理區域的市場表現的全面回顧，透過識別高成長地區和區域趨勢，可以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點，或針對特定細分市場的深入洞察，以更好地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球肺癌治療市場：依疾病類型分類

• 市場分析、洞察與預測
• 非小細胞肺癌（NSCLC）
• 小細胞肺癌（SCLC）
• 其他

第5章：全球肺癌治療市場：依治療方法

• 市場分析、洞察與預測
• 化療
• 免疫療法
• 標靶治療

第6章 全球肺癌治療市場：依藥物類別分類

• 市場分析、洞察與預測
• 小分子藥物
• 生物製劑和生物相似藥

第7章 全球肺癌治療市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 網路藥房

第8章：全球肺癌治療市場：依治療階段分類

• 市場分析、洞察與預測
• 一線治療
• 第二行
• 從第三行開始

第9章 全球肺癌治療市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第10章 競爭格局

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第11章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca PLC
  • Merck & Co.Inc
  • Bristol Myers Squibb Company
  • Pfizer Inc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly And Company
  • Novartis AG
  • Johnson & Johnson
  • AbbVie Inc
  • Amgen Inc
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Daiichi Sankyo Company, Limited
  • BeiGeneLtd

The global lung cancer therapeutics market size is expected to reach USD 89.63 Billion in 2034 from USD 30.68 Billion in 2025, growing at a CAGR of 12.65 during 2026-2034.This market is experiencing strong growth due to the increasing prevalence of lung cancer and rising demand for advanced treatment solutions worldwide. Growing awareness regarding early diagnosis and improved access to healthcare services are supporting market expansion. Pharmaceutical companies are investing heavily in targeted therapies, immunotherapies, and personalized medicine approaches to improve patient survival rates. Technological advancements in molecular diagnostics and precision oncology are also contributing significantly to the development of innovative therapeutic options.

Rising tobacco consumption, air pollution, and aging populations are major factors driving the demand for lung cancer therapeutics. Healthcare providers are increasingly adopting targeted drugs and immune checkpoint inhibitors because of their effectiveness and reduced side effects compared to traditional chemotherapy. Growing research and development activities in oncology and increasing clinical trials for novel therapies are further strengthening market growth. In addition, supportive government initiatives and cancer awareness programs are positively influencing treatment adoption globally.

Future prospects for the market remain highly promising due to continuous advancements in biotechnology and cancer research. Development of personalized treatment solutions based on genetic profiling is expected to improve therapeutic outcomes significantly. Emerging economies are projected to witness substantial growth because of improving healthcare infrastructure and increasing cancer screening initiatives. As the global burden of lung cancer continues to rise, the market is anticipated to experience sustained long-term expansion across healthcare sectors.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)
• Others

By Treatment Modality

• Chemotherapy
• Immunotherapy
• Targeted Therapy

By Drug Class

• Small-Molecule Drugs
• Biologics and Biosimilars

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Line of Therapy

• First-Line
• Second-Line
• Third-Line and Beyond

COMPANIES PROFILED

• F. Hoffmann-La Roche Ltd., AstraZeneca PLC, Merck & Co., Inc., Bristol Myers Squibb Company, Pfizer Inc., Boehringer Ingelheim International GmbH, Eli Lilly and Company, Novartis AG, Johnson & Johnson, AbbVie Inc., Amgen Inc., Sanofi, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Company, Limited, BeiGene, Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Non-Small Cell Lung Cancer (NSCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Small Cell Lung Cancer (SCLC) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT MODALITY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Treatment Modality
• 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Drug Class
• 6.2. Small-Molecule Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Biologics and Biosimilars Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY LINE OF THERAPY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Line Of Therapy
• 8.2. First-Line Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Second-Line Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Third-Line and Beyond Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Disease Type
  • 9.2.2 By Treatment Modality
  • 9.2.3 By Drug Class
  • 9.2.4 By Distribution Channel
  • 9.2.5 By Line Of Therapy
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Disease Type
  • 9.3.2 By Treatment Modality
  • 9.3.3 By Drug Class
  • 9.3.4 By Distribution Channel
  • 9.3.5 By Line Of Therapy
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Disease Type
  • 9.4.2 By Treatment Modality
  • 9.4.3 By Drug Class
  • 9.4.4 By Distribution Channel
  • 9.4.5 By Line Of Therapy
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Disease Type
  • 9.5.2 By Treatment Modality
  • 9.5.3 By Drug Class
  • 9.5.4 By Distribution Channel
  • 9.5.5 By Line Of Therapy
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Disease Type
  • 9.6.2 By Treatment Modality
  • 9.6.3 By Drug Class
  • 9.6.4 By Distribution Channel
  • 9.6.5 By Line Of Therapy
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL LUNG CANCER THERAPEUTICS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd
  • 11.2.2 AstraZeneca PLC
  • 11.2.3 Merck & Co.Inc
  • 11.2.4 Bristol Myers Squibb Company
  • 11.2.5 Pfizer Inc
  • 11.2.6 Boehringer Ingelheim International GmbH
  • 11.2.7 Eli Lilly And Company
  • 11.2.8 Novartis AG
  • 11.2.9 Johnson & Johnson
  • 11.2.10 AbbVie Inc
  • 11.2.11 Amgen Inc
  • 11.2.12 Sanofi
  • 11.2.13 Takeda Pharmaceutical Company Limited
  • 11.2.14 Daiichi Sankyo Company, Limited
  • 11.2.15 BeiGeneLtd